Akèy › Emofili
Etid klinik pou Emofili ap rekrite nan Etazini
28 etid pou Emofili ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Indianapolis, IN8 etid
- Los Angeles, CA7 etid
- Seattle, WA6 etid
- Cedar Rapids, IA6 etid
- Philadelphia, PA5 etid
- Sacramento, CA4 etid
- Atlanta, GA4 etid
- Little Rock, AR4 etid
- Greenville, NC4 etid
- Tampa, FL4 etid
- Orange, CA4 etid
- Dallas, TX4 etid
- Boston, MA3 etid
- Kansas City, MO3 etid
- Detroit, MI3 etid
- Harrisburg, PA3 etid
- Chicago, IL3 etid
- San Francisco, CA3 etid
- St. Louis, MO3 etid
- Cincinnati, OH3 etid
- San Antonio, TX3 etid
- Aurora, CO3 etid
Pa eta
- Arkansas4 etid
- Colorado3 etid
- Florid6 etid
- Georgia4 etid
- Illinois4 etid
- Indiana8 etid
- Iowa6 etid
- Kalifòni14 etid
- Massachusetts3 etid
- Michigan5 etid
- Missouri5 etid
- New York4 etid
- North Carolina6 etid
- Ohio5 etid
- Pennsylvania6 etid
- Texas8 etid
- Washington6 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
TG-INSIGHT With Joint POCUS, Hemostatic Potential in Patients With Severe Hemophilia A on Novel Replacement and Substitution FVIII Therapies
Ap rekriteEtid obsèvasyon
6 Months · Tout sèks · Mizajou Sep 29, 2026 · NCT07692217A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
Ap rekriteFaz 3
Laj 1 a 17 · Gason · Mizajou Sep 23, 2026 · NCT05611801Treatment of Hemophilia A Patients With FVIII Inhibitors
Ap rekriteEtid obsèvasyon
Tout laj · Gason · Mizajou Sep 23, 2026 · NCT04023019A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
Ap rekriteFaz 4
Laj 12 ak plis · Gason · Mizajou Sep 23, 2026 · NCT06145373A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
Ap rekriteFaz 3
Laj 12 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07416526A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 64 · Gason · Mizajou Sep 18, 2026 · NCT07220564A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
Ap rekriteFaz 1/2
Laj 2 a 59 · Gason · Mizajou Sep 11, 2026 · NCT05987449A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
Ap rekriteFaz 1/2
Laj 18 ak plis · Gason · Mizajou Sep 11, 2026 · NCT07226206A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
Ap rekriteFaz 3
Laj 12 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT07416604Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 0 a 20 · Tout sèks · Mizajou Aug 21, 2026 · NCT04278404SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
Ap rekriteFaz 3
Laj 6 ak plis · Tout sèks · Mizajou Aug 21, 2026 · NCT04563520ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Aug 17, 2026 · NCT04398628A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
Ap rekriteFaz 3
Laj 1 a 11 · Gason · Mizajou Aug 17, 2026 · NCT07285460Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis
Ap rekriteEtid obsèvasyon
Laj 6 a 19 · Tout sèks · Mizajou Jul 2, 2026 · NCT05022459A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 60 · Tout sèks · Mizajou Jul 2, 2026 · NCT06349473Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Ap rekriteFaz 3
Laj 1 a 74 · Gason · Mizajou Jul 1, 2026 · NCT05145127A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
Ap rekriteFaz 1
Laj 12 a 74 · Gason · Mizajou Jun 3, 2026 · NCT06703606Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jun 2, 2026 · NCT03695978Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
Ap rekriteFaz 3
Laj 18 ak plis · Gason · Mizajou May 27, 2026 · NCT05568719Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
Ap rekriteFaz 4
Laj 12 ak plis · Fanm · Mizajou May 12, 2026 · NCT05936580Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
Ap rekriteFaz 4
Laj 12 ak plis · Gason · Mizajou May 12, 2026 · NCT05935358ATHNdataset Registry
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Apr 21, 2026 · NCT06820515Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
Ap rekriteFaz 1
Laj 0 a 90 · Tout sèks · Mizajou Apr 3, 2026 · NCT05500807Hemophilia A Research Program
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Tout laj · Tout sèks · Mizajou Feb 17, 2026 · NCT07414511SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
Ap rekriteFaz 4
Laj 12 a 100 · Tout sèks · Mizajou Jan 12, 2026 · NCT04647227Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.